The intracellular pharmacology of antiretroviral protease inhibitors.
about
The role of drug transporters in the kidney: lessons from tenofovirDrug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug deliveryUltra-fast analysis of plasma and intracellular levels of HIV protease inhibitors in children: a clinical application of MALDI mass spectrometryGlobal expression of molecular transporters in the human vaginal tract: implications for HIV chemoprophylaxisInfluence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trialDifferential expression of breast cancer-resistance protein, lung resistance protein, and multidrug resistance protein 1 in retinas of streptozotocin-induced diabetic mice.Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" studyHIV protease inhibitors disrupt lipid metabolism by activating endoplasmic reticulum stress and inhibiting autophagy activity in adipocytesEvaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.Binary and ternary combinations of anti-HIV protease inhibitors: effect on gene expression and functional activity of CYP3A4 and efflux transporters.Saquinavir inhibits the malaria parasite's chloroquine resistance transporter.Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy.Biphasic elimination of tenofovir diphosphate and nonlinear pharmacokinetics of zidovudine triphosphate in a microdosing studyPlasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.As in humans, pregnancy increases the clearance of the protease inhibitor nelfinavir in the nonhuman primate Macaca nemestrinaLeishmania panamensis infection and antimonial drugs modulate expression of macrophage drug transporters and metabolizing enzymes: impact on intracellular parasite survival.HIV protease inhibitors: recent clinical trials and recommendations on use.Therapeutic drug monitoring in highly active antiretroviral therapy.Expression and induction by dexamethasone of ABC transporters and nuclear receptors in a human T-lymphocyte cell line.Liquid chromatography-mass spectrometry methods for the intracellular determination of drugs and their metabolites: a focus on antiviral drugs.Saquinavir Loaded Acetalated Dextran Microconfetti - a Long Acting Protease Inhibitor Injectable.Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir.Plasma and Intracellular Antiretroviral Concentrations in HIV-Infected Patients under Short Cycles of Antiretroviral Therapy.Intracellular efavirenz levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected individualsAtazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms.Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells.Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters.Quantitative immunoassay to measure plasma and intracellular atazanavir levels: analysis of drug accumulation in cultured T cells.The antiretroviral protease inhibitors indinavir and nelfinavir stimulate Mrp1-mediated GSH export from cultured brain astrocytes.Gene expression modulation and the molecular mechanisms involved in Nelfinavir resistance in Leishmania donovani axenic amastigotes.High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life.Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy.The antiretroviral protease inhibitor ritonavir accelerates glutathione export from cultured primary astrocytes.Pharmacokinetic Changes during Pregnancy According to Genetic Variants: A Prospective Study in HIV-infected Patients Receiving Atazanavir/Ritonavir.
P2860
Q26866489-01B0DB82-8A8B-44EE-A716-CC5A12379F3BQ28081272-A2EDD24B-6637-4FAF-BF1F-FE8009DB0BEFQ28474772-CD8F04E3-3DFD-4A76-8BE7-A16CDD2FD1FDQ28534412-229ADBC3-EFF2-4D0C-8E4A-7B7B3B8B9D6DQ33348311-A1419999-7559-408A-AD08-6EC690068554Q33607716-0AED8153-656A-425E-A273-AFCE5371937FQ33776536-753C78DA-9F3D-4FC2-AFA1-74DBDB94EED0Q34151189-D7C210C3-FC38-4C85-A19A-5C1BB4449204Q34534986-EE0AE74E-2C88-409A-BDA8-81CAD0F6726FQ34637857-4E3882F9-D38C-4DD8-9F96-0FE34E88CDE2Q35005018-2BA5D64F-49A2-44B6-8B36-C5C46231E645Q35531564-A2C64221-4874-4CCE-A479-D81F6583FD6FQ35941244-1CCC17F9-3B13-44AF-85CE-156C41FFE7B2Q36235489-77B1BD5E-0475-49F5-946B-A7A419212A90Q36432228-1D7C3A00-EF50-42D6-958C-EB9389E1482FQ36675900-70A2ABB3-557F-463E-AE3F-C26B3B16471FQ37113947-1C0DB058-005B-4C28-8C84-5436A01DDFC8Q37196307-01C81808-DFC5-4FF8-81FF-0558EA6BCE58Q37388291-F7595ECC-91EC-4822-BAD2-33D405F2A943Q37519715-C4276E6A-52FE-44FA-8AA2-A43B280F0739Q37720765-9B486511-7B37-496E-AC51-460696582F44Q39356163-AD5E4419-B778-4710-9755-F278532DE350Q39434360-68C60ACF-3F11-483C-A475-5945EE168582Q39787241-202DF329-5EF6-4DAB-9E01-59AECA947ED2Q41139969-AC911ECE-4C60-42EF-9EB4-058590F3C8FBQ41644790-6C0B8FEC-0F0A-47B4-B0BA-8B947A377B91Q41915254-DB0A6F24-0FD5-412B-B346-2B3FFFABD197Q41992990-34875B8F-6603-49FD-970E-3F6427F6C1CFQ42207349-F36F80F6-90E6-4B98-AD26-0FD28D8F2AECQ42283464-FFCE8D10-6835-4DED-A3A8-8B3E994BBC07Q42491474-0A089F00-3E7C-4624-9591-2D83F7952935Q42956763-28EB1FC1-DDD1-4445-832E-50DB21BECF73Q44176745-011EE238-C39C-46D9-BB1B-91EDAE0BC7FDQ45302847-23648D66-43C6-4221-9990-E02A0EBFB825Q46226197-3DD8EF80-83DC-417D-AEB8-C219F7A94BE5Q46791174-DFF3A51E-153E-4375-8EE7-89C604AE2444Q48198876-E3EA5653-20AF-41A5-B944-884D8197021CQ54212183-34D1A154-BA1E-44BB-8883-121505B3A439
P2860
The intracellular pharmacology of antiretroviral protease inhibitors.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The intracellular pharmacology of antiretroviral protease inhibitors.
@ast
The intracellular pharmacology of antiretroviral protease inhibitors.
@en
type
label
The intracellular pharmacology of antiretroviral protease inhibitors.
@ast
The intracellular pharmacology of antiretroviral protease inhibitors.
@en
prefLabel
The intracellular pharmacology of antiretroviral protease inhibitors.
@ast
The intracellular pharmacology of antiretroviral protease inhibitors.
@en
P2093
P356
P1476
The intracellular pharmacology of antiretroviral protease inhibitors.
@en
P2093
P304
P356
10.1093/JAC/DKH487
P407
P577
2004-11-10T00:00:00Z